1. Rugo HS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). Program and abstracts of the American Society of Clinical Oncology Annual Meeting and Exposition; 1–5 June 2012; Chicago. Abstract CRA1002.
2. Miller KD. Can efficacy be derailed by toxicity? Posted online 07/02/2012. www.medscape.com/viewarticle/766488_print .
3. Flanagan JC. A research approach to improving our quality of life. Am Psychol. 1978;33:138–47.
4. Flanagan JC. Measurement of the quality of life: current state of the art. Arch Phys Med Rehabil. 1982;63:56–9.
5. EORTC quality of life. Glossary. http://groups.eortc.be/qol/glossary .